WHATโ€™S HAPPENING AT APDA

Falls Prevention Did you know that September was Falls Prevention Awareness Month? Throughout the month,...see more we raised awareness through social media, emails, and conversations with the PD community. Some common causes of falls in PD are postural instability, freezing of gait, festinating gait, orthostatic hypotension, and more. Physical therapy and medication […]

Read More

Making Hope Possible: American Parkinson Disease Associationย Supports Researchers With $2.6 Million in New Fundingย 

Supports Researchers With $2.6 Million in New Funding  From genetic causes of Parkinsonโ€™s to the neurobiology of cognitive dysfunction,...see more APDA-funded researchers begin new work.  NEW YORK, NY, SEPTEMBER 4, 2024 โ€“ The American Parkinson Disease Association (APDA) has just awarded $2.6 million to support innovative Parkinsonโ€™s disease (PD) research for the 2024-2025 funding year โ€“ […]

Read More

Adaptive DBS โ€“ a new approach to improve PD symptoms

Deep brain stimulation (DBS) is a surgical procedure in which thin electrodes are implanted into parts of the brain...see more to alter brain circuitry. It is used in the treatment of several neurologic conditions including Parkinsonโ€™s disease (PD), in which the electricity disrupts abnormal brain signals that allows the brain to restore more normal movement. Currently, […]

Read More

Recently published research on induced pluripotent stem cells by APDA-funded researchers

APDA-funded researchers at Brigham and Womenโ€™s Hospital, including Drs. Isabel Lam and Anastasia Kuzkina, under the leadership of Dr. ...see more Vikram Khurana, the Director of APDAโ€™s Center for Advanced Research at Brigham and Womenโ€™s Hospital, recently published a paper demonstrating a novel technology that more rapidly turns stem cells created from the cells of an adult […]

Read More

Crexontยฎ: A Newly Approved Parkinson’s Medication

Newย Carbidopa/Levodopa Formulationย Approved for Reducing OFF Time Amneal Pharmaceuticals, Inc. announced today that their new medication IPX203, now known as...see more Crexontยฎ, was approved by the Food and Drug Administration. Crexont is a novel oral formulation of carbidopa-levodopa extended-release capsules. Similar to Amnealโ€™s Rytary, it contains both immediate-release and extended-release elements in the capsule and is designed […]

Read More